Mahmoud Pouladi

Pouladi Mahmoud

  • Assistant Professor, Department of Medicine
Joint Appointment(s)
  • Associate Director, Translational Laboratory in Genetic Medicine, A*STAR
  • Principal Investigator, Translational Laboratory in Genetic Medicine, A*STAR
Academic Qualifications
  • PhD (Medical Genetics), University of British Columbia, Canada
  • MSc (Immunology), McMaster University, Canada
  • BSc (Molecular Biology), McMaster University, Canada
Research Interest(s)
  • Dementia
  • Huntington Disease
  • Fragile X Syndrome
  • Disease Modelling
  • Human Pluripotent Stem Cells
  • Target Discovery and Validation
Recent Publications
  • 1. Bardile, C. F., Garcia-Miralles, M., Caron, N. S., Rayan, N. A., Langley, S. R., Harmston, N., . . . Pouladi, M. A. (2019). Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116(19), 9622-9627. doi:10.1073/pnas.1818042116.
  • 2. van Kuilenburg, A. B. P., Tarailo-Graovac, M., Richmond, P. A., Drogemoller, B. I., Pouladi, M. A., Leen, R., . . . van Karnebeek, C. D. M. (2019). Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. NEW ENGLAND JOURNAL OF MEDICINE, 380(15), 1433-1441. doi:10.1056/NEJMoa1806627.
  • 3. Ooi, J., Langley, S. R., Xu, X., Utami, K. H., Sim, B., Huang, Y., . . . Pouladi, M. A. (2019). Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects. CELL REPORTS, 26(9), 2494-+. doi:10.1016/j.celrep.2019.02.008.
  • 4. Garcia-Miralles, M., Geva, M., Tan, J. Y., Yusof, N. A. B. M., Cha, Y., Kusko, R., . . . Pouladi, M. A. (2017). Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI INSIGHT, 2(23), 18 pages. doi:10.1172/jci.insight.95665.
  • 5. Xu, X., Tay, Y., Sim, B., Yoon, S. -I., Huang, Y., Ooi, J., . . . Pouladi, M. A. (2017). Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. STEM CELL REPORTS, 8(3), 619-633. doi:10.1016/j.stemcr.2017.01.022.